Další formáty:
BibTeX
LaTeX
RIS
@article{1365669,
author = {Koudelka, Stepan and Mikulík, Robert and Mašek, Josef and Raška, Milan and Knotigová, Pavlína Turánek and Miller, Andrew D. and Turánek, Jaroslav},
article_location = {Amsterdam},
article_number = {"neuvedeno"},
doi = {http://dx.doi.org/10.1016/j.jconrel.2016.02.019},
keywords = {Fibrin; Liposomes; Platelets; Protein delivery; RGD peptide; Streptokinase; Stroke; Thrombus; Tissue plasminogen activator; Urokinase},
language = {eng},
issn = {0168-3659},
journal = {Journal of Controlled Release},
title = {Liposomal nanocarriers for plasminogen activators},
volume = {227},
year = {2016}
}
TY - JOUR
ID - 1365669
AU - Koudelka, Stepan - Mikulík, Robert - Mašek, Josef - Raška, Milan - Knotigová, Pavlína Turánek - Miller, Andrew D. - Turánek, Jaroslav
PY - 2016
TI - Liposomal nanocarriers for plasminogen activators
JF - Journal of Controlled Release
VL - 227
IS - "neuvedeno"
SP - 45-57
EP - 45-57
PB - Elsevier Science BV
SN - 01683659
KW - Fibrin
KW - Liposomes
KW - Platelets
KW - Protein delivery
KW - RGD peptide
KW - Streptokinase
KW - Stroke
KW - Thrombus
KW - Tissue plasminogen activator
KW - Urokinase
N2 - Several plasminogen activators (PAs) have been found effective in treating different thromboembolic diseases. However, administration of conventional thrombolytic therapy is limited by a low efficacy of present formulations of PAs. Conventional treatments using these therapeutic proteins are associated with several limitations including rapid inactivation and clearance, short half-life, bleeding complications or non-specific tissue targeting. Liposome-based formulations of PAs such as streptokinase, tissue-plasminogen activator and urokinase have been developed to improve the therapeutic efficacy of these proteins. Resulting liposomal formulations were found to preserve the original activity of PAs, promote their selective delivery and improve thrombus targeting. Therapeutic potential of these liposome-based PAs has been demonstrated successfully in various pre-clinical models in vivo. Reductions in unwanted side effects (e.g., hemorrhage or immunogenicity) as well as enhancements of efficacy and safety were achieved in comparison to currently existing treatment options based on conventional formulations of PAs. This review summarizes present achievements in: (i) preparation of liposome-based formulations of various PAs, (ii) development of PEGylated and targeted liposomal PAs, (iii) physicochemical characterization of these developed systems, and (iv) testing of their thrombolytic efficacy. We also look to the future and the imminent arrival of theranostic liposomal formulations to move this field forward.
ER -
KOUDELKA, Stepan, Robert MIKULÍK, Josef MAŠEK, Milan RAŠKA, Pavlína Turánek KNOTIGOVÁ, Andrew D. MILLER a Jaroslav TURÁNEK. Liposomal nanocarriers for plasminogen activators. \textit{Journal of Controlled Release}. Amsterdam: Elsevier Science BV, roč.~227, ''neuvedeno'', s.~45-57. ISSN~0168-3659. doi:10.1016/j.jconrel.2016.02.019. 2016.
|
